ArticleESMO real world data and digital oncology2026
Data resource profile: National Cancer Registry Ireland.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: National Cancer Registry Ireland (NCRI) is the state agency responsible for collecting and analysing data on all cancer patients to help improve health outcomes in Ireland. Established by the Minister for Health under Statutory Instrument 19/1991, it began collecting data in 1994 from both public and private health care providers. Materials and methods: NCRI data come from multiple sources, including hospital pathology laboratories, radiotherapy units, medical records, and death certification systems, providing near-complete national coverage and strong longitudinal follow-up. Using internationally recognised coding systems, including International Classification of Diseases for Oncology, Tumour-Node-Metastasis, World Health Organization tumour classification and Australian Classification of Health Interventions, NCRI collects data on patient demographics, tumour characteristics, stage at diagnosis, treatment, and survival. The data undergo rigorous quality assurance procedures to ensure accuracy, completeness, and comparability over time and with international datasets. Results: As of March 2026, for years 1994-2025, the NCRI held data on 1 131 145 tumours (International Classification of Diseases, 10th Revision, C00-96, D00-48) diagnosed in 883 967 individuals. An average of 36 078 invasive cancers [including nonmelanoma skin cancer (NMSC)] per year were diagnosed during 2019-2023, accounting for ∼0.75% of the population. The most common tumour sites registered during this period were NMSC, prostate, breast, lung, and colorectal. NCRI demonstrated high data quality, with low levels of death certificate-only cases (<1%), unknown primary sites (1.3%), and unspecified morphology (7.5%) and high microscopic verification (92.3%). Conclusion: NCRI is a comprehensive resource for cancer surveillance, service planning, policy development, and research. Enhanced linkages and expansion of data collection would improve NCRI's capacity to inform cancer research, policy development, and evidence-based improvements in cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.